HMPV: Much Ado About 'Nothing', Say Doctors
Infectious disease specialists have termed the human metapneumovirus "reasonably innocuous", urging calm amid concerns over the HMPV.
Ramasubramanian, a consultant on infectious diseases at Apollo Hospitals, dismissed the frenzy, labelling it a "hue and cry over nothing".
HMPV, a respiratory virus discovered over two decades ago but circulating for 60–80 years, is akin to the common cold. Its symptoms — nasal congestion, blocked nose and mild fever — are typically harmless in healthy adults, according to Ramasubramanian.
In adults, it doesn't even cause fever.Ramasubramanian, consultant on infectious diseases, Apollo Hospitals
For the most part, the virus is a concern only for young children, the elderly and those with a compromised immune system. Even in these groups, it rarely poses a serious threat unless accompanied by breathlessness or a significant drop in oxygen levels, Ramasubramanian explained.
Often mentioned in the same breath as the respiratory syncytial virus, the HMPV shares similarities in being aerosol-transmitted and seasonal, typically surfacing in the winter months. But experts are quick to note key differences.
"RSV often causes wheezing in otherwise healthy individuals. HMPV tends to worsen pre-existing conditions like asthma but is otherwise mild," Ramasubramanian said.
There is no vaccine for HMPV primarily because its impact is minor. Preventative measures like masking, maintaining distance and practicing hygiene suffice, though most children in schools are likely to catch viral infections anyway, according to Vinit Samdhani, a pediatrician at Breach Candy Hospital.
Despite media reports spotlighting HMPV in China, doctors emphasise that no unusual outbreaks or severe cases are being observed. "This is a normal winter virus," Samdhani said. "History shows pandemics occur every 100 years. We're far from the next one."
While HMPV is generally mild, doctors advise watching out for severe symptoms like breathlessness, high fever or low oxygen levels, which may warrant hospitalisation. However, for the vast majority, symptomatic treatment at home is sufficient.
Watch Conversation
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.